Related references
Note: Only part of the references are listed.Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease
Claire Painchart et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2019)
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2019)
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Konstantinos Papamichael et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
Tu1829 – Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohns Disease
Christine Verdon et al.
GASTROENTEROLOGY (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
Akbar K. Waljee et al.
JAMA NETWORK OPEN (2019)
Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
C. R. Rowan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
J C Marini et al.
Journal of Crohns & Colitis (2018)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease
Orlaith B. Kelly et al.
INFLAMMATORY BOWEL DISEASES (2017)
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
Greg Rosenfeld et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases
Edmond Y. Huang et al.
INFLAMMATORY BOWEL DISEASES (2015)
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis A Step Toward Personalized Treatment
Stef P. Menting et al.
JAMA DERMATOLOGY (2015)
Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease
Brian Bressler et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
R. Khanna et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Share Paper
